title: Serum prolactin, leptin, lipids and lipoproteins levels during antipsychotics treatment in Parkinson's disease and related psychosis.
abstract: Weight gain is a common adverse effect associated with the use of most typical and atypical antipsychotic. Aim of this study was to investigate serum prolactin, leptin, cholesterol, triglyceride, lipoproteins, such high density lipoprotein (HDL), and low density lipoprotein (LDL) levels in patients with Parkinson's disease (PD)-related psychosis during long-term medication with atypical antipsychotic. The study population comprised 40 patients, who were divided into 4 groups: olanzapine (n=10), risperidone (n=10), seroquel (n=10) monotherapy, a group of 10 patients receiving only antiparkinson drugs and a control group of 8 healthy persons. The patients were evaluated at baseline and at the sixth and twelfth week according to the Positive and Negative Syndrome Scale (PANSS), body mass index (BMI), and fasting serum prolactin, leptin, lipids and lipoproteins levels. Treatment of patients with olanzapine caused marked increase of serum LDL, cholesterol, triglyceride, and leptin levels (p<0,02). No changes in HDL concentrations. There was positive relationship between serum leptin, lipid levels and BMI. However, treatment of patients with seroquel did not cause changes in serum prolactin, leptin, lipids, and lipoproteins levels. Our results suggest that treatment of patients with PD-related psychosis with seroquel appears to have minimal influence on serum leptin, prolactin, lipids, lipoproteins and BMI compared with olanzapine and risperidone.
authors.affiliation: Anton Proksch Institute of Drug and Alcohol Dependence, Vienna, Austria.
authors.forename: Avdo
authors.initials: A
authors.lastname: Rustembegovic
authors.forename: Emin
authors.initials: E
authors.lastname: Sofic
authors.forename: Ildiko
authors.initials: I
authors.lastname: Wichart
mesh_terms: D000978:Antiparkinson Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000627:therapeutic use; D015992:Body Mass Index; D003987:Dibenzothiazepines / Q000627:therapeutic use; D006801:Humans; D020738:Leptin / Q000097:blood*; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood*; D000077152:Olanzapine; D010300:Parkinson Disease / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D011618:Psychotic Disorders / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D000069348:Quetiapine Fumarate; D018967:Risperidone / Q000627:therapeutic use
chemical_list: D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D020738:Leptin; D008055:Lipids; D008074:Lipoproteins; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; D018967:Risperidone; D000077152:Olanzapine